publications
IXICO uses its proprietary AI-driven platform to advance the treatment of neurological disorders and reduce uncertainties in drug discovery, development, and monitoring.
The IXI™ Platform deploys cutting-edge AI technology to generate imaging biomarker insights specific to neurological diseases, combined with expert clinical trial operations to help accelerate decision-making in clinical research and maximise the potential of drug development programmes.
IXICO has built a global reputation as a leading end-to-end Imaging Contract Research Organisation (iCRO), expertly managing and analysing neurological clinical trials.
The Company is a key part of the global neurological disease research community, with a 20-year proven track record in the biopharmaceutical industry, working with leading pharma companies, innovative biotechs, scientific consortia, and non-profit organisations.
The IXI™ Platform is tailor-made for neurological diseases, reliably managing global clinical trial data, precisely reading radiological scans, and measuring key imaging biomarkers linked to the identification, progression, and treatment of conditions such as Alzheimer’s, Huntington’s, and Parkinson’s disease.
